A federal judicial panel said Monday it would centralize a growing number of lawsuits against Novo Nordisk and Eli Lilly ...
In the midst of regulatory and political upheaval, biopharma’s R&D engine kept running, churning out highs and lows in equal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback